Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Analysis of 3346 patients from the combined Children's Oncology Group AML studies further characterizes RAM immunophenotype AML and reveals other associated phenotypes and genetic drivers.

Andrew Menssen, Jacqueline Cook, Todd Alonzo, Robert Gerbing, Maria Pardo, Fan-Chi Hsu, Loren Lott, Fangyan Dai, Amenech Ashango, Thanh Thanh Dinh, Todd Cooper, Jessica Pollard, Katherine Tarlock, Lisa Brodersen, Michael Loken, Soheil Meshinchi, Chad Hudson

Blood (2025) 146 (Supplement 1): 337.

https://doi.org/10.1182/blood-2025-337

Published: 2025

Journal Articles

Etoposide can be safely removed from induction chemotherapy without impacting survival for pediatric acute myeloid leukemia – a report from the Children's oncology group study AAML1831

Jenna Rossoff, Jing Chen, Todd Alonzo, Jim Wang, Richard Aplenc, Alan Gamis, Betsy Hirsch, Gordana Raca, Soheil Meshinchi, Anders Kolb, Sarah Tasian, Jessica Pollard, Matthew Kutny, Todd Cooper

Blood (2025) 146 (Supplement 1): 877.

https://doi.org/10.1182/blood-2025-877

Published: 2025

Journal Articles

Central nervous system disease status significantly impacts survival in pediatric acute myeloid leukemia: A report from Children's Oncology Group study AAML1831

Zachary Graff, Todd Alonzo, Robert Gerbing, Jim Wang, Jessica Pollard, Soheil Meshinchi, Alan Gamis, Richard Aplenc, Betsy Hirsch, Gordana Raca, Todd Cooper, Matthew Kutny

Blood (2025) 146 (Supplement 1): 872.

https://doi.org/10.1182/blood-2025-872

Published: 2025

Journal Articles

FLT3 (CD135) expression in pediatric AML is associated with specific disease characteristics and worse outcome in the setting of sorafenib theraphy: A report from the Children's Oncology Group AAML1031 protocol.

Andrew Menssen, Amenech Ashango, Todd Alonzo, Robert Gerbing, Maria Pardo, Fan-Chi Hsu, Loren Lott, Fangyan Dai, Todd Cooper, Jessica Pollard, Katherine Tarlock, Richard Aplenc, Soheil Meshinchi, Lisa Brodersen, Michael Loken, Chad Hudson

Blood (2025) 146 (Supplement 1): 5256.

https://doi.org/10.1182/blood-2025-5256

Published: 2025

Journal Articles

Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831

Reena Pabari, Chana Glasser, Todd Alonzo, Jim Wang, Richard Aplenc, Alan Gamis, Betsy Hirsch, Gordana Raca, Soheil Meshinchi, Kasey Leger, Kelly Getz, Anders Kolb, Jessica Pollard, Sarah Tasian, Matthew Kutny, Todd Cooper

Blood (2025) 146 (Supplement 1): 878.

https://doi.org/10.1182/blood-2025-878

Published: 2025

Journal Articles

Post-transplant maintenance with sorafenib is safe and effective in pediatric patients with har FLT3/ITD AML: A report from the Children's oncology group protocol AAML1031

Caitlin Elgarten, Todd Alonzo, Robert Gerbing, John Choi, Brian Fisher, Betsy Hirsch, Samir Kahwash, John Levine, Lisa Brodersen, Michael Loken, Susana Raimondi, Katherine Tarlock, Andrew Wood, Lillian Sung, Todd Cooper, Alan Gamis, Soheil Meshinchi, Richard Aplenc, Jessica Pollard

Blood (2025) 146 (Supplement 1): 1644.

https://doi.org/10.1182/blood-2025-1644

Published: 2025

Journal Articles

NUP98::NSD1 fusion is associated with poor outcomes in Acute Myeloid Leukemia regardless of co-occurring mutations and treatment regimen

Katherine Tarlock, Danielle Kirkey, Rhonda Ries, Jack H. Peplinski, Todd Alonzo, Robert Gerbing, Jim Wang, Todd Cooper, Alan Gamis, Richard Aplenc, Martina Pigazzi, Franco Locatelli, Jessica Pollard, Soheil Meshinchi

Blood (2025) 146 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2025-1702

Published: 2025

Journal Articles

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Blood (2021) 138 (23): 2337–2346.

https://doi.org/10.1182/blood.2021012206

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia

Katherine Tarlock, Todd Alonzo, Yi-Cheng Wang, Robert B. Gerbing, Rhonda E. Ries, Tiffany Hylkema, Jenny L. Smith, Julia E. Maxson, Soheil Meshinchi

Blood (2020) 135 (18): 1603–1606.

https://doi.org/10.1182/blood.2019004179

Published: 2020

Includes: Supplemental data

Journal Articles

High EVI1 expression Is Associated with MLL rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children's Oncology Group.

Phoenix A. Ho, MD, Todd Alonzo, PhD, Robert B. Gerbing, M.A., Jessica A. Pollard, MD, Susana C. Raimondi, Betsy A. Hirsch, PhD, Todd Cooper, DO, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 2530.

https://doi.org/10.1182/blood.V120.21.2530.2530

Published: 2012

Journal Articles

Identification of Novel Somatic Mutations, Regions of Recurrent Loss of Heterozygosity (LOH) and Significant Clonal Evolution From Diagnosis to Relapse in Childhood AML Determined by Exome Capture Sequencing – an NCI/COG Target AML Study

Soheil Meshinchi, MD, PhD, Rhonda E. Ries, MA, Lisa R. Trevino, PhD, Oliver A. Hampton, PhD, Todd Alonzo, PhD, Jason E. Farrar, MD, Jaime M. Guidry Auvil, PhD, Tanja M. Davidsen, PhD, Patee Gesuwan, PhD, Donna M. Muzny, Alan S. Gamis, MD, MPH, Heather L. Helton, MD, David A. Wheeler, PhD, Malcolm A. Smith, MD, PhD, Daniela S. Gerhard, Ph.D., Robert J. Arceci, MD, PhD

Blood (2012) 120 (21): 123.

https://doi.org/10.1182/blood.V120.21.123.123

Published: 2012

Journal Articles

COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML)

Janet Franklin, MD, MPH, Todd Alonzo, PhD, Craig Alan Hurwitz, MD, Robert Gerbing, Franklin Smith, Robert J. Arceci, MD, PhD, James Feusner, MD, Prasad Mathew, MD, Robert Iannone, MD, Soheil Meshinchi, MD, PhD, Robert Lavey, MD, MPH, Joetta D Wallace, RN, Kelly Anderson, RN, Laura Winter, PharmD, Kathleen Glick, BA, Betty Hirsch, MD, Susana C. Raimondi, PhD, Alan Gamis, MD

Blood (2008) 112 (11): 136.

https://doi.org/10.1182/blood.V112.11.136.136

Published: 2008

Journal Articles

Functional Polymorphisms in Oxidant Metabolism and DNA Repair Pathways and Risk of Leukemia and Transient Myeloproliferative Disorder in Children with Down Syndrome

Melissa S Rayburg, MD, Mi-Ok Kim, Todd Alonzo, PhD, Robert Gerbing, Gretchen A Radloff, Stella M Davies, Alan Gamis, MD, John Perentesis

Blood (2008) 112 (11): 2947.

https://doi.org/10.1182/blood.V112.11.2947.2947

Published: 2008

Journal Articles

High Level Expression of Wild Type FLT3 Is Associated with Poor Outcome and Selective Sensitivity to FLT3 Inhibitors in Childhood Acute Myeloid Leukemia: A Children’s Oncology Group Study

Patrick Brown, MD, Todd Alonzo, PhD, Robert Gerbing, Emily McIntyre, Beverly Lange, MD, Donald Small, Soheil Meshinchi, MD, PhD

Blood (2008) 112 (11): 147.

https://doi.org/10.1182/blood.V112.11.147.147

Published: 2008

Journal Articles

Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group

Jessica A Pollard, Rong Zeng, Phoenix Ho, Todd Alonzo, PhD, Robert Gerbing, Derek Stirewalt, Nyla A. Heerema, PhD, Susana C. Raimondi, PhD, Betsy Hirsch, Janet Franklin, MD, MPH, Beverly Lange, MD, Soheil Meshinchi, MD, PhD

Blood (2008) 112 (11): 143.

https://doi.org/10.1182/blood.V112.11.143.143

Published: 2008

Journal Articles

Correlation of CD 33 Expression Level with Disease Characteristics and Response to Gemtuzumab Ozogamycin-Containing Chemotherapy in Childhood AML

Jessica A Pollard, Todd Alonzo, PhD, Robert Gerbing, Susana C. Raimondi, PhD, Betsy Hirsch, Janet Franklin, MD, MPH, Alan Gamis, MD, Michael R Loken, Soheil Meshinchi, MD, PhD

Blood (2008) 112 (11): 148.

https://doi.org/10.1182/blood.V112.11.148.148

Published: 2008

Journal Articles

Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants.

Alena Y. Zhang, PharmD, PhD, Blaine W. Robinson, PhD, Kajia Kao, PhD, Kathryn Behling, MD, PhD, Meenakshi Devidas, PhD, Todd Alonzo, PhD, Susana C. Raimondi, PhD, Andrew Carroll, PhD, Robert J. Arceci, MD, PhD, Alan Gamis, MD, Stephen P. Hunger, MD, Gregory H. Reaman, MD, Richard C. Harvey, PhD, Cheryl L. Willman, MD, Li-San Wang, PhD, Carolyn A. Felix, MD

Blood (2008) 112 (11): 2255.

https://doi.org/10.1182/blood.V112.11.2255.2255

Published: 2008

Journal Articles

Clinical and Serologic Interleukin 2 Receptor α Response to Interleukin-2 in CCG-2961, a Ranomized Phase 3 Trial for Pediatric Acute Myeloid Leukemia.

Beverly Lange, MD, Richard K Yang, Jacek Gan, PhD, Jaqueline A Hank, PhD, Eric Sievers, MD, Robert Gerbing, Todd Alonzo, PhD, Paul M Sondel, MD, PhD

Blood (2008) 112 (11): 959.

https://doi.org/10.1182/blood.V112.11.959.959

Published: 2008

Journal Articles

Pediatric Patients with Extramedullary Leukemia Involving the Central Nervous System Have a Superior Outcome.

Donna Johnston, MD, FRCPC, Todd Alonzo, PhD, Robert Gerbing, Beverly Lange, MD, William G. Woods, MD

Blood (2008) 112 (11): 920.

https://doi.org/10.1182/blood.V112.11.920.920

Published: 2008

Journal Articles

Minimal Residual Disease Detection by Four-Color Multidimensional Flow Cytometry Identifies Pediatric AML Patients at High Risk of Relapse.

Soheil Meshinchi, MD, PhD, Todd Alonzo, PhD, Robert B. Gerbing, MA, Jessica A. Pollard, MD, Alan S. Gamis, MD, MPH, Craig A. Hurwitz, MD, Janet L. Franklin, MD, Laura Pardo, MD, Michael Loken, PhD

Blood (2007) 110 (11): 1429.

https://doi.org/10.1182/blood.V110.11.1429.1429

Published: 2007

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Analysis of 3346 patients from the combined Children's Oncology Group AML studies further characterizes RAM immunophenotype AML and reveals other associated phenotypes and genetic drivers.

Etoposide can be safely removed from induction chemotherapy without impacting survival for pediatric acute myeloid leukemia – a report from the Children's oncology group study AAML1831

Central nervous system disease status significantly impacts survival in pediatric acute myeloid leukemia: A report from Children's Oncology Group study AAML1831

FLT3 (CD135) expression in pediatric AML is associated with specific disease characteristics and worse outcome in the setting of sorafenib theraphy: A report from the Children's Oncology Group AAML1031 protocol.

Optimized treatment for pediatric patients with low-risk Acute Myeloid Leukemia: A report from the Children's oncology group study AAML1831

Post-transplant maintenance with sorafenib is safe and effective in pediatric patients with har FLT3/ITD AML: A report from the Children's oncology group protocol AAML1031

NUP98::NSD1 fusion is associated with poor outcomes in Acute Myeloid Leukemia regardless of co-occurring mutations and treatment regimen

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia

High EVI1 expression Is Associated with MLL rearrangements and Predicts Decreased Survival in Pediatric AML: A Report From the Children's Oncology Group.

Identification of Novel Somatic Mutations, Regions of Recurrent Loss of Heterozygosity (LOH) and Significant Clonal Evolution From Diagnosis to Relapse in Childhood AML Determined by Exome Capture Sequencing – an NCI/COG Target AML Study

COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML)

Functional Polymorphisms in Oxidant Metabolism and DNA Repair Pathways and Risk of Leukemia and Transient Myeloproliferative Disorder in Children with Down Syndrome

High Level Expression of Wild Type FLT3 Is Associated with Poor Outcome and Selective Sensitivity to FLT3 Inhibitors in Childhood Acute Myeloid Leukemia: A Children’s Oncology Group Study

Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group

Correlation of CD 33 Expression Level with Disease Characteristics and Response to Gemtuzumab Ozogamycin-Containing Chemotherapy in Childhood AML

Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants.

Clinical and Serologic Interleukin 2 Receptor α Response to Interleukin-2 in CCG-2961, a Ranomized Phase 3 Trial for Pediatric Acute Myeloid Leukemia.

Pediatric Patients with Extramedullary Leukemia Involving the Central Nervous System Have a Superior Outcome.

Minimal Residual Disease Detection by Four-Color Multidimensional Flow Cytometry Identifies Pediatric AML Patients at High Risk of Relapse.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only